Apimeds Pharmaceuticals US Inc

Apimeds Pharmaceuticals US Inc. resolves legal dispute, lifts trading freeze, shares rebound to $1.88, boosting investor confidence and trading volume.

Apimeds Pharmaceuticals US Inc. is developing a groundbreaking treatment called Apitox, a bee venom-based toxin for osteoarthritis, which could offer new hope for patients suffering from knee pain.

Apimeds Pharmaceuticals US Inc. is a clinical-stage biopharmaceutical company developing Apitox, a bee venom-based treatment for osteoarthritis, with the potential to offer new hope to patients who have not responded to existing therapies.